The National Filariasis Elimination Program (NFEP) is a comprehensive initiative led by the Department of Health (DOH) to eradicate lymphatic filariasis, a debilitating parasitic disease. Lymphatic filariasis, transmitted through mosquito bites, is the second leading parasitic disease affecting the lymphatic system, causing long-term disabilities such as lymphedema and hydrocele. The program, launched in 1998, works in partnership with organizations such as the Coalition for the Elimination of Lymphatic Filariasis (CELF) Philippines, the Department of Education, the Department of Social Welfare and Development, and other public and private entities.
Target BeneficiariesThe program serves residents of endemic provinces, covering individuals aged two years and older. Its primary goal is to prevent the spread of lymphatic filariasis while managing and alleviating its effects on affected individuals.
Key Components of the Program
- Mass Drug Administration (MDA). The cornerstone of the NFEP is annual Mass Drug Administration. All individuals aged two and older in endemic areas receive two medications:
- Albendazole. Supplied by GlaxoSmithKline through DOH.
- Diethylcarbamazine Citrate (DEC). Provided by DOH.
These medications are distributed once a year for five consecutive years, aiming to interrupt the transmission cycle of the disease. If the area achieves an 85% participation rate and reduces its microfilaremia rate to below 0.1% for five years, it may be declared filariasis-free by the World Health Organization (WHO).
- Disability Management. The program addresses the long-term impacts of lymphatic filariasis by teaching patients how to manage symptoms such as swelling and deformities. This includes hygiene practices and techniques to prevent reinfection or further complications.
- Hydrocelectomy. For patients with severe cases, such as hydrocele (swelling of the scrotum), surgical intervention is provided. Hydrocelectomy restores physical function and allows patients to return to their normal activities and livelihoods.
Sustaining LF-Free StatusOnce a province is declared lymphatic filariasis-free, DOH provides grants to maintain its status. Continuous monitoring, screening, and testing ensure that the disease does not re-emerge in the area.
Availability of MedicinesThe medications for lymphatic filariasis are available at all health centers in endemic provinces. The DOH, along with GlaxoSmithKline and other stakeholders, ensures a steady supply of drugs through its regional Centers for Health and Development.
How to Access the ProgramResidents of endemic areas can visit their local health centers to participate in the program. Medicines are free of charge, making it accessible to communities most in need.
Contact InformationFor inquiries about the National Filariasis Elimination Program, you may contact:
- DOH Infectious Disease OfficeAttn: Dr. Leda HernandezPhone: (632) 651-7800
- Coalition for the Elimination of Lymphatic Filariasis (CELF) PhilippinesPhone: 0915-329-6997
The Path Toward EliminationThe National Filariasis Elimination Program represents a significant step in combating one of the most debilitating parasitic diseases in the Philippines. Through collaboration, public awareness, and sustained efforts, the DOH and its partners aim to eradicate lymphatic filariasis, improving the lives of affected individuals and protecting future generations from its burden.
